| pubmed-article:19331709 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19331709 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
| pubmed-article:19331709 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19331709 | lifeskim:mentions | umls-concept:C0393022 | lld:lifeskim |
| pubmed-article:19331709 | lifeskim:mentions | umls-concept:C1511726 | lld:lifeskim |
| pubmed-article:19331709 | lifeskim:mentions | umls-concept:C0010181 | lld:lifeskim |
| pubmed-article:19331709 | lifeskim:mentions | umls-concept:C0034975 | lld:lifeskim |
| pubmed-article:19331709 | lifeskim:mentions | umls-concept:C0870071 | lld:lifeskim |
| pubmed-article:19331709 | lifeskim:mentions | umls-concept:C0038995 | lld:lifeskim |
| pubmed-article:19331709 | lifeskim:mentions | umls-concept:C1710133 | lld:lifeskim |
| pubmed-article:19331709 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19331709 | pubmed:dateCreated | 2009-4-15 | lld:pubmed |
| pubmed-article:19331709 | pubmed:abstractText | The aim of this study was to estimate the cost-effectiveness of rituximab in patients not responding adequately to the first tumor necrosis factor (TNF) inhibitor using a model constructed to predict resource consumption and health outcomes in a population-based registry of biological treatments in Southern Sweden (SSATG). | lld:pubmed |
| pubmed-article:19331709 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19331709 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19331709 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19331709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19331709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19331709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19331709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19331709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19331709 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19331709 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:19331709 | pubmed:issn | 1471-6348 | lld:pubmed |
| pubmed-article:19331709 | pubmed:author | pubmed-author:LindgrenPeter... | lld:pubmed |
| pubmed-article:19331709 | pubmed:author | pubmed-author:KobeltGiselaG | lld:pubmed |
| pubmed-article:19331709 | pubmed:author | pubmed-author:GeborekPierre... | lld:pubmed |
| pubmed-article:19331709 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19331709 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:19331709 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19331709 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19331709 | pubmed:pagination | 181-9 | lld:pubmed |
| pubmed-article:19331709 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:meshHeading | pubmed-meshheading:19331709... | lld:pubmed |
| pubmed-article:19331709 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19331709 | pubmed:articleTitle | Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. | lld:pubmed |
| pubmed-article:19331709 | pubmed:affiliation | i3/innovus, Klarabergsviadukten 90D, SE-111 64 Stockholm, Sweden. Peter.Lindgren@3innovus.com | lld:pubmed |
| pubmed-article:19331709 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19331709 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19331709 | lld:pubmed |
